Expert Ratings For Blueprint Medicines
Expert Ratings For Blueprint Medicines
Blueprint Medicines的專家評級
During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，有17名分析師分享了他們對 Blueprint Medicines（納斯達克：BPMC）的評估，展示了從看好到看淡的不同觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60.
在12個月價格目標的評估中，分析師揭示了 Blueprint Medicines 的見解，呈現出平均目標爲116.35美元，最高估價爲168.00美元，最低估價爲75.00美元。目前的平均數已比先前的平均價格目標101.60美元上漲了14.52%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The standing of Blueprint Medicines among financial...
最近分析師行動...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。